Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

BACKGROUND: The aim of our study was to evaluate the cost-effectiveness of cabazitaxel versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who had progression within 12 months while receiving an alternative inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng-Fei, Xie, Dan, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791718/
https://www.ncbi.nlm.nih.gov/pubmed/33413230
http://dx.doi.org/10.1186/s12885-020-07754-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791718/
https://www.ncbi.nlm.nih.gov/pubmed/33413230
http://dx.doi.org/10.1186/s12885-020-07754-9

Ejemplares similares